[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458027":3},{"organization":4,"outcomesModule":7,"designInfo":37,"detailedDescription":49,"studyPopulation":36,"armGroups":50,"interventions":61,"overallOfficials":36,"centralContacts":36,"locations":67,"responsibleParty":91,"collaborators":93,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":104,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":36,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":70,"whyStopped":36,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":36},[9],{"measure":10,"description":11,"timeFrame":12},"ADR","The adenoma detection rate (ADR) is defined as the proportion of colonoscopies with at least 1 histopathologically proven adenoma or carcinoma detected.","30 days",[14,17,20,23,26,29,32],{"measure":15,"description":16,"timeFrame":12},"Mean number of adenomas per colonoscopy (APC)","Mean number of adenomas per colonoscopy (APC) defined as the total number of adenomas divided by the number of colonoscopies performed",{"measure":18,"description":19,"timeFrame":12},"Sessile serrated lesions (SSL) detection rate","Sessile serrated lesions (SSL) detection rate as the proportion of patients colonoscopy in whom superior or equal to 1 sessile serrated lesion (SSL) is identified",{"measure":21,"description":22,"timeFrame":12},"Sessile serrated lesion per Colonoscopy (SSLPC)","Sessile serrated lesion per Colonoscopy (SSLPC), defined as the total number of histologically confirmed sessile serrated lesions resected divided by the total number of colonoscopies",{"measure":24,"description":25,"timeFrame":12},"Advanced lesion detection rate (ALDR)","Advanced lesion detection rate (ALDR), defined as the proportion of colonoscopies for which the number of histopathologically proven adenoma \\>10mm was at least 1.",{"measure":27,"description":28,"timeFrame":12},"Proximal ADR","Proximal ADR is defined as the prevalence of patients with at least 1 adenoma detected proximal to the splenic flexure",{"measure":30,"description":31,"timeFrame":12},"Proportion neoplastic and non-neoplastic polyps","Proportion neoplastic and non-neoplastic polyps (i.e., SSLs, hyperplastic polyps, and high-grade dysplasia and carcinomas (overall and according to size, location, and morphology)",{"measure":33,"description":34,"timeFrame":35},"CADe utilization rate","CADe utilization rate (when available in the room). Since the CADe utilization rate cannot be assessed without revealing the ongoing trial to the endoscopists, two voluntary self-reported measures and a partially objective measure. First, endoscopists will be surveyed via email during and at the end of the trial regarding their use of CADe, while keeping them unaware of the ongoing trial. Second, the proportion with endoscopy reports for which is is explicitly stated that CADe was used will be computed.","Through study completion, an average of 3 years",null,{"allocation":38,"interventionModel":39,"interventionModelDescription":40,"primaryPurpose":41,"observationalModel":36,"timePerspective":36,"maskingInfo":42},"RANDOMIZED","PARALLEL","pragmatic double-blinded, randomized, multi-endoscopist, multicenter","DIAGNOSTIC",{"masking":43,"maskingDescription":44,"whoMasked":45},"TRIPLE","Allocation will be concealed; the patients and the participating endoscopists will not be informed of the treatment group.",[46,47,48],"PARTICIPANT","CARE_PROVIDER","OUTCOMES_ASSESSOR","This trial will be conducted in four centers across Canada. All patients who meet the in\u002Fexclusion criteria can be enrolled. The patient's personal medical history will be reviewed to verify patient inclusion and exclusion criteria (age, history of CRC or adenoma, comorbid conditions, anticoagulation, etc.).\n\nEligible patients will be randomized (1:1) stratified per center, endoscopist, sex, and age group in two arms:\n\n1. Intervention arm: patients will be assigned to undergo colonoscopy in a room equipped with the GI genius CADe system.\n2. Control arm: patients will undergo colonoscopy in a room not equipped with the GI genius CADe system.\n\nThe endoscopists performing the colonoscopies will not be involved in the development and implementation of CADe. Additionally, they won't be informed of the ongoing trial and will have the option of not using the CADe when available in the room. This design aims to mitigate operator biases that may be partly responsible for the observed difference between the CADe performance in randomized controlled trials and the CADe performance in implementation studies.\n\nData will be collected on case report forms (CRF), after the procedure, from the clinical files and the endoscopy reports. The data will then be deidentified and transferred to an electronic RedCap database in each institution. A research assistant will collect all information and annotations recorded on the patient's medical file during the procedure.\n\nIn the treatment group (operating room equipped with the CADe), the Medtronic-GI genius system can be used for real-time support by the endoscopists to detect polyps of all sizes. Use of CADe is left to the discretion of the treating physician performing the colonoscopy. If used, CADe will provide real-time feedback throughout each colonoscopy procedure and will alert the endoscopists of the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.\n\nIn the control group (colonoscopy performed in room without CADe system), the participating endoscopists will detect as per standard of care.\n\nAll colonoscopies (in the intervention and control groups) including polypectomy procedures will be performed at the discretion of the treating physician and per standard of care.\n\nAll polyps will be resected as per standard of care and sent to the pathology labs of the participating institutions to be evaluated for histology by board-certified pathologists. The histopathology outcomes will be collected and stored in the CRF forms to be used as a reference later.",[51,57],{"label":52,"type":53,"description":54,"interventionNames":55},"Operating room equipped with the CADe (Medtronic-GI genius for real-time detection)","EXPERIMENTAL","The Medtronic-GI genius (CADe) system can be used to detect polyps of all sizes. Use of CADe is left to the discretion of the treating physician performing the colonoscopy. If used CADe will provide real-time feedback throughout each colonoscopy procedure and will alert the endoscopists of the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.",[56],"Device: Medtronic-GI genius (CADe system for detecting colorectal polyps)",{"label":58,"type":59,"description":60,"interventionNames":36},"Colonoscopy performed in room without CADe system","NO_INTERVENTION","In the control group (standard colonoscopy), the participating endoscopists will detect and classify colorectal lesions without using any AI modules.",[62],{"type":63,"name":64,"description":65,"armGroupLabels":66,"otherNames":36},"DEVICE","Medtronic-GI genius (CADe system for detecting colorectal polyps)","Medtronic-GI genius: AI will provide real-time feedback throughout each colonoscopy procedure and alert endoscopists to the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.",[52],[68],{"facility":69,"status":70,"city":71,"state":72,"zip":36,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"Centre Hospitalier Universitaire de Montréal","RECRUITING","Montreal","Quebec","Canada","CA",{"type":76,"coordinates":77},"Point",[78,79],-73.58781,45.50884,{"lat":79,"lon":78},[82,88],{"name":83,"role":84,"phone":85,"phoneExt":86,"email":87},"Samira Hanin","CONTACT","514-890-8000","30916","samira.hanin.chum@ssss.gouv.qc.ca",{"name":89,"role":90,"phone":36,"phoneExt":36,"email":36},"Daniel von Renteln, MD, PhD","PRINCIPAL_INVESTIGATOR",{"type":92,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[94,96,98,100],{"name":95,"class":6},"McGill University",{"name":97,"class":6},"University of British Columbia",{"name":99,"class":6},"Université de Sherbrooke",{"name":101,"class":6},"University of Alberta","100458027","artificial-intelligence-ai-assisted-real-time-adenoma-detection-and-classification-during-colonoscopies-100458027",false,"NCT05244278","Artificial Intelligence (AI) Assisted Real-time Adenoma Detection and Classification During Colonoscopies","CAG-SIG-AI","Inclusion Criteria:\n\n* indication of undergoing a screening, surveillance, or diagnostic colonoscopy\n* Age 45-89 years\n\nExclusion Criteria:\n\n* Patients undergoing emergency colonoscopy\n* Patients with a known familial polyposis syndrome or a known inflammatory bowel disease","ALL","45 Years","89 Years",{"count":113,"type":114},1596,"ESTIMATED","INTERVENTIONAL",[117],"NA","This is a pragmatic, double-blind, randomized, controlled trial, to evaluate the effect of implementing a Computer-assisted detection (CADe) system within the routine clinical practice of Canadian healthcare institutions.\n\nThe main hypothesis of this study is that the ADR in the operating room equipped with the GI genius CADe system will be significantly higher than the ADR in the ordinary operating room.",[120],"Artificial Intelligence",[122,123,124,125,126],"Polyp detection","Adenoma detection","Adenoma per colonoscopy","Sessile serrated lesion detection rate","Sessile serrated lesion per colonoscopy","2026-09-17",{"date":129,"type":130},"2026-09-21","ACTUAL",{"date":132,"type":130},"2023-08-01",{"date":134,"type":114},"2027-01-01",{"name":5,"class":6},1]